Literature DB >> 19805902

Single-nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma and their association with plasma levels of resistin and the metabolic syndrome in a South Indian population.

Abdul Haseeb1, Mohammad Iliyas, Subhabrata Chakrabarti, Arif A Farooqui, Sudhir R Naik, Sudip Ghosh, Madhuri Suragani, Nasreen Z Ehtesham.   

Abstract

Studies on the association of the Pro12Ala and C1431T polymorphisms of PPAR? with diabetes and obesity have revealed extensive population-dependent variations. However, association of these polymorphisms with the metabolic syndrome and its individual components has not been well investigated in the Indian population. The Indian population harbours the maximum number of diabetics in the world who are thus more susceptible to metabolic disorders. We screened a South Indian population (N=699) for a possible association of these polymorphisms with the metabolic syndrome (MS) and type 2 diabetes. We also investigated the correlation of these two single-nucleotide polymorphisms (SNPs) with plasma resistin levels. The C1431T SNP was associated with higher levels of plasma resistin (P=0.017). Furthermore, C1431T was associated with resistin in different tertiles. Prevalence of the 'Pro-C' haplotype decreased with increasing tertiles of resistin (84.1% to 75.4%, P=0.037). Plasma resistin levels were not found to be associated with MS and type 2 diabetes. These results point to a likely association of plasma resistin levels with PPAR? polymorphisms in the Indian population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805902     DOI: 10.1007/s12038-009-0047-x

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  38 in total

1.  A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans.

Authors:  A Meirhaeghe; L Fajas; N Helbecque; D Cottel; P Lebel; J Dallongeville; S Deeb; J Auwerx; P Amouyel
Journal:  Hum Mol Genet       Date:  1998-03       Impact factor: 6.150

2.  Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women.

Authors:  Aline Meirhaeghe; Dominique Cottel; Philippe Amouyel; Jean Dallongeville
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

3.  Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects.

Authors:  E Y Oh; K M Min; J H Chung; Y K Min; M S Lee; K W Kim; M K Lee
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

4.  An analysis of peroxisome proliferator-activated receptor gamma (PPAR-gamma 2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits.

Authors:  R Scacchi; A Pinto; O Rickards; A Pacella; G F De Stefano; C Cannella; R M Corbo
Journal:  Nutr Metab Cardiovasc Dis       Date:  2007-04-16       Impact factor: 4.222

5.  Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway.

Authors:  Nirupama Silswal; Anil K Singh; Battu Aruna; Sangita Mukhopadhyay; Sudip Ghosh; Nasreen Z Ehtesham
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

6.  Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome.

Authors:  Laura Frederiksen; Kasper Brødbaek; Mogens Fenger; Torben Jørgensen; Knut Borch-Johnsen; Sten Madsbad; Søren A Urhammer
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

7.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

8.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

9.  Absence of Association of Metabolic Syndrome with PPARGC1A, PPARG and UCP1 Gene Polymorphisms in Asian Indians.

Authors:  K S Vimaleswaran; V Radha; R Deepa; V Mohan
Journal:  Metab Syndr Relat Disord       Date:  2007-06       Impact factor: 1.894

10.  Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators.

Authors:  Lisa Patel; Amy C Buckels; Ian J Kinghorn; Paul R Murdock; Joanna D Holbrook; Christopher Plumpton; Colin H Macphee; Stephen A Smith
Journal:  Biochem Biophys Res Commun       Date:  2003-01-10       Impact factor: 3.575

View more
  13 in total

1.  Development of ARMS-PCR assay for genotyping of Pro12Ala SNP of PPARG gene: a cost effective way for case-control studies of type 2 diabetes in developing countries.

Authors:  Mehboob Islam; Fazli Rabbi Awan; Shahid Mahmood Baig
Journal:  Mol Biol Rep       Date:  2014-07-26       Impact factor: 2.316

2.  Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations?

Authors:  Zahra N Sohani; Wei Q Deng; Guillaume Pare; David Meyre; Hertzel C Gerstein; Sonia S Anand
Journal:  Diabetologia       Date:  2014-08-22       Impact factor: 10.122

3.  Variation in PPARG is associated with longitudinal change in insulin resistance in Mexican Americans at risk for type 2 diabetes.

Authors:  Mary Helen Black; Jun Wu; Miwa Takayanagi; Nan Wang; Kent D Taylor; Talin Haritunians; Enrique Trigo; Jean M Lawrence; Richard M Watanabe; Thomas A Buchanan; Anny H Xiang
Journal:  J Clin Endocrinol Metab       Date:  2015-01-13       Impact factor: 5.958

4.  Impact of the PPAR gamma-2 gene polymorphisms on the metabolic state of postmenopausal women.

Authors:  Bogna Grygiel-Gorniak; Maria Mosor; Justyna Marcinkowska; Juliusz Przyslawski; Jerzy Nowak
Journal:  J Biosci       Date:  2016-09       Impact factor: 1.826

5.  Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians.

Authors:  Surya Prakash Bhatt; Anoop Misra; Mukti Sharma; Kalpana Luthra; Randeep Guleria; Ravindra Mohan Pandey; Naval K Vikram
Journal:  Diabetes Technol Ther       Date:  2012-06-13       Impact factor: 6.118

6.  G Allele of the rs1801282 Polymorphism in PPARγ Gene Confers an Increased Risk of Obesity and Hypercholesterolemia, While T Allele of the rs3856806 Polymorphism Displays a Protective Role Against Dyslipidemia: A Systematic Review and Meta-Analysis.

Authors:  Shujin Li; Chuan He; Haiyan Nie; Qianyin Pang; Ruixia Wang; Zhifu Zeng; Yongyan Song
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

7.  PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues.

Authors:  Valerio Costa; Maria Assunta Gallo; Francesca Letizia; Marianna Aprile; Amelia Casamassimi; Alfredo Ciccodicola
Journal:  PPAR Res       Date:  2010-09-08       Impact factor: 4.964

8.  Inflammation, a link between obesity and cardiovascular disease.

Authors:  Zhaoxia Wang; Tomohiro Nakayama
Journal:  Mediators Inflamm       Date:  2010-08-05       Impact factor: 4.711

9.  Screening of Peroxisome Proliferator-Activated Receptors (PPARs) α, γ and α Gene Polymorphisms for Obesity and Metabolic Syndrome Association in the Multi-Ethnic Malaysian Population.

Authors:  Phee-Phee Chia; Sook-Ha Fan; Yee-How Say
Journal:  Ethn Dis       Date:  2015-11-05       Impact factor: 1.847

10.  Association of PPARG Pro12Ala polymorphism with insulin sensitivity and body mass index in patients with polycystic ovary syndrome.

Authors:  Dinka Pavicic Baldani; Lana Skrgatic; Jasmina Z Cerne; Polonca Ferk; Velimir Simunic; Ksenija Gersak
Journal:  Biomed Rep       Date:  2013-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.